NEXGEL, Inc. (NXGL) Earnings
NEXGEL, Inc. is expected to report next earnings on August 11, 2026 (in NaN days), with a consensus EPS estimate of $-0.12. NXGL has beaten EPS estimates in 4 of its last 12 reported quarters (average surprise -217.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 15, 2026 | $-0.07 | $-0.11 | -57.1% | $3M | -32.2% |
| Mar 31, 2026 | $-0.09 | $-0.12 | -33.3% | $3M | -13.7% |
| Aug 12, 2025 | $-0.01 | $-0.09 | -800.0% | $3M | -16.4% |
| Mar 24, 2025 | $-0.10 | $-0.08 | +20.0% | $3M | +11.6% |
| Aug 19, 2024 | $-0.14 | $-0.14 | +0.0% | $1M | +2.5% |
| Apr 1, 2024 | $-0.11 | $-0.19 | -72.7% | $1M | -1.5% |
| Nov 13, 2023 | $-0.12 | $-0.10 | +16.7% | $1M | +1.8% |
| Aug 14, 2023 | $-0.13 | $-0.12 | +7.7% | $1M | +16.7% |
| May 15, 2023 | $-0.14 | $-0.15 | -7.1% | $620000 | +37.8% |
| Aug 10, 2022 | $-0.15 | $-0.19 | -26.7% | $561000 | +22.0% |
| May 12, 2022 | $-0.15 | $-0.33 | -120.0% | $396000 | -21.1% |
| Mar 21, 2022 | $-0.37 | $-0.29 | +20.4% | $533000 | +27.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 15, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Acquisition of Bionics Division * Closed the bionics division acquisition in mid-April 2026, financed by a $13.8 million total raise: $8.8 million in cash, and a $5 million convertible note delivered to Cellularity. Sequence Life Science led a $5.5 million strategic investment, replacing a short-term financial lender with a long-term strategic growth partner. * The Bionics portfolio includes 6 commercial-stage regenerative biomaterial products with over 10 years of clinical use, existing reimbursement pathways, and approval for use in ~500 U.S. hospitals across multiple surgical specialties and wound care. There are 3 additional 510(k) devices in the development pipeline, with $4.6 million in invested paid-in capital, targeted for commercialization between 2026 and 2028. * Added an experienced commercial and scientific team with the acquisition, expanding NextGel's internal capabilities for medical device development. Appointed Dave Hazard as Vice President of Sales for Bionic Surgical, who brings 13 years of sales leadership in orthopedics, spine, and biologics to scale commercial operations. * Sequence Life Science CEO Brian J. Kieser and COO Kevin Harris joined NextGel's board of directors, bringing deep industry experience and an expanded distribution network. - Organizational Updates * Appointed Ian Blackman as new CFO, a veteran M&A and financial leader tasked with leading acquisition integration and scaling the business for growth. Management states the company's board and senior leadership team is now the strongest in its history. - Legacy Business Updates * The KISS nail products legal case has been settled. Higher Q1 SG&A was primarily driven by acquisition-related costs and this legal case settlement. * Silly George has been repositioned after underperformance, and new products (such as a new tweezers line) are already performing strongly, with revenue returning to normalized levels in April 2026. * Stata products are growing nicely; the second Stata product launched in early 2026 hit the market in mid-February after minor Amazon logistics delays. Tropilastin products have shipped from Germany and are expected to launch on Amazon within 60 days. * As of March 31, 2026, cash and restricted cash totaled ~$2.1 million; current cash on hand as of the call is $1.8 million.
Guidance
- Pro forma annual revenue after the bionics acquisition is expected to reach roughly $35 million, tripling legacy annual revenue, and the acquisition will be immediately accretive to profitability upon closing. - Only modest (approximately 10%) growth is baked into current projections for the legacy non-bionics business, a conservative assumption; management expects to outperform this projection, with recovery already visible in Silly George and ongoing growth in contract manufacturing and Medi-gel. - Bionics division revenue will only be included for roughly half of Q2 2026, as sales ramping only began in mid-May after completion of post-acquisition transition tasks (contract reissuance, compliance training, vendor account updates). - The three pipeline 510(k) devices are targeted for commercialization in 2026, 2027, and 2028 respectively. - NextGel will report Q2 2026 results and provide more detailed acquisition integration updates in August 2026.
Segment performance
Q1 2026 total revenue was $2.65 million, a slight decrease from $2.81 million in Q1 2025 (year-over-year revenue was relatively flat overall): - Silly George (consumer product segment): Q1 2026 sales came in lower year-over-year following an uncharacteristically weak Q4 2025, offset partially by growth in other segments. This segment has already shown revenue normalization and recovery in April 2026, ahead of inclusion in full Q2 results. - Contract manufacturing: Revenue grew year-over-year in Q1 2026, partially offsetting the Silly George sales decline. - Medi-gel brand (including Stata products): Revenue grew year-over-year in Q1 2026, partially offsetting the Silly George sales decline. - Bionics division: No revenue was included in Q1 2026 results, as the acquisition closed in mid-April 2026. On a pro forma basis, the acquisition is expected to bring NextGel's total annual revenue to approximately $35 million, roughly tripling the company's annual revenue from its legacy business.
Risks & headwinds
- Forward-looking statements are subject to material risks and uncertainties that could cause actual results to differ materially from projections; detailed risk disclosures are available in the company's periodic SEC filings. - Consumer product segment performance can be unpredictable, as seen with the underperformance of new Silly George lip gloss products in late 2025 and early 2026, leading management to use conservative growth projections for the legacy consumer business. - New medical device contract manufacturing accounts require 510(k) clearance, creating uncertainty around the timing of revenue ramp for new pipeline opportunities. - The acquisition is a transformative step change, and successful integration and revenue ramp of the Bionics division depends on completing post-acquisition operational transitions and expanding commercial adoption.
Analyst Q&A
Q: After closing the bionics acquisition, how long has the sales team been promoting the products, and have you seen improved performance versus the prior owner's run rate? /
A: No meaningful sales activity occurred pre-closing, as the asset was not yet under NextGel ownership. Post-closing, several weeks of work were required to finalize new sales contracts, complete sunshine act compliance training, update hospital account vendor information, and other transition tasks. Sales reps only began ramping outreach in mid-May 2026, so no results are yet available, and management is optimistic for the second half of Q2. (307 characters)
Q: The projection to triple annual revenue assumes the legacy non-bionics business stays flat, or does it include expected growth? Also, what is the expected annual increase in normalized operating expenses after adding new bionics sales and R&D staff? /
A: The projection uses a very conservative, very low growth assumption for the legacy business, even though management expects modest growth (with Silly George already recovering in April). The approximate new normalized monthly run rate for added bionics operating overhead (salaries, marketing, commissions, all-in) is $500,000. (312 characters)
Q: Why has the legacy business moved from 100% year-over-year growth to flat revenue, and can you provide an update on key legacy pipeline and customer relationships? /
A: The flat revenue projection is conservative, driven by recent underperformance of new Silly George consumer products amid heavy competition, though the segment has already recovered in April after repositioning. Key legacy programs are progressing: new Stata products are growing, Tropilastin will launch soon, contract manufacturing and Medi-gel continue to grow. iRhythm has been a smaller customer than initially projected, but remains a steady customer, and other potential contract manufacturing accounts are still in the pipeline with uncertain timing due to regulatory clearance requirements. (478 characters)
Q: What is the status of the laser hair removal product development, and when might it generate revenue? /
A: The clinical trial for the product was recently published, with outstanding results: a 96% reduction in plume, plus improved pain outcomes and efficacy. The trial was sponsored and paid for by Innovative Optics, which will market the product to large laser manufacturers and purchases components from NextGel. The company just received the published results, so marketing is just getting underway, and revenue depends on their commercial success. (349 characters)